首页 / 院系成果 / 成果详情页

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 期刊论文 WOS高被引论文 WOS热点论文

编号：

EF65F2289EB6D66787BF03474DAC0208
作者：

Cao, B.(曹彬)#*^[1,3]Wang, Y.(王业明)#^[1,3]Wen, D.#^[11]Liu, W.#^[11]Wang, Jingli#^[11]Fan, G.(范国辉)#^[1,2]Ruan, L.#^[11]Song, B.#^[11]Cai, Y.#^[11]Wei, M.#^[11]Li, X.^[4];Xia, J.^[11];Chen, N.^[11];Xiang, J.^[11];Yu, T.^[11];Bai, T.^[11];Xie, X.^[11];Zhang, L.^[11];Li, C.^[11];Yuan, Y.^[11];Chen, H.^[11];Li, Huadong^[11];Huang, H.^[11];Tu, S.^[11];Gong, F.^[11];Liu, Y.^[11];Wei, Y.^[11];Dong, C.^[5];Zhou, F.(周飞)^[1,3]Gu, X.(谷晓颖)^[1,2]Xu, J.^[6];Liu, Z.(刘智博)^[1,3]Zhang, Y.(张祎)^[1,3]Li, Hui(李辉)^[1,3]Shang, L.(商潋瀚)^[1,7]Wang, K.^[11];Li, K.^[11];Zhou, X.^[11];Dong, X.^[11];Qu, Z.^[11];Lu, S.^[11];Hu, X.^[11];Ruan, S.^[11];Luo, S.^[11];Wu, J.^[11];Peng, L.^[11];Cheng, F.^[11];Pan, L.^[11];Zou, J.^[11];Jia, C.^[11];Wang, Juan^[11];Liu, X.^[11];Wang, S.^[11];Wu, X.^[11];Ge, Q.^[11];He, J.^[11];Zhan, H.^[11];Qiu, F.^[11];Guo, L.^[8,9,10];Huang, C.^[11];Jaki, T.^[12];Hayden, F. G.^[14];Horby, P. W.^[13];Zhang, D.#*^[11]Wang, C.(王辰)#*^[1,3,10]
语种：

英文
期刊：

NEW ENGLAND JOURNAL OF MEDICINE ISSN：0028-4793 2020 年 382 卷 19 期 (1787 - 1799) ; MAY 7
收录：
摘要：

BACKGROUND
No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.
METHODS
We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao(2)) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao(2)) to the fraction of inspired oxygen (Fio(2)) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.
RESULTS
A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.
CONCLUSIONS
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.)
推荐引用方式
GB/T 7714：

Cao B.,Wang Y.,Wen D., et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 [J].NEW ENGLAND JOURNAL OF MEDICINE,2020,382(19):1787-1799.
APA：

Cao B.,Wang Y.,Wen D.,Liu W.,&Wang C..(2020).A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 .NEW ENGLAND JOURNAL OF MEDICINE,382(19):1787-1799.
MLA：

Cao B., et al. "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19" .NEW ENGLAND JOURNAL OF MEDICINE 382,19(2020):1787-1799.
入库时间：

6/2/2020 1:29:10 AM
更新时间：

6/2/2020 1:29:10 AM
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：234  下载次数：0

分享到：

浏览次数：234

下载次数：0

打印次数：9